The estimated Net Worth of Douglas E Williams is at least $4.6 Milión dollars as of 28 March 2023. Dr Williams owns over 41,667 units of Codiak BioSciences stock worth over $436 and over the last 21 years he sold CDAK stock worth over $3,740,263. In addition, he makes $863,681 as Pres a CEO & Director at Codiak BioSciences.
Dr has made over 17 trades of the Codiak BioSciences stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 41,667 units of CDAK stock worth $7,500 on 28 March 2023.
The largest trade he's ever made was exercising 45,938 units of Codiak BioSciences stock on 16 August 2022 worth over $2,618. On average, Dr trades about 3,262 units every 112 days since 2003. As of 28 March 2023 he still owns at least 7,655 units of Codiak BioSciences stock.
You can see the complete history of Dr Williams stock trades at the bottom of the page.
Dr. Douglas Edward Williams Ph.D. is the Pres, CEO & Director at Codiak BioSciences.
As the Pres a CEO & Director of Codiak BioSciences, the total compensation of Dr D at Codiak BioSciences is $863,681. There are no executives at Codiak BioSciences getting paid more.
Dr D is 63, he's been the Pres a CEO & Director of Codiak BioSciences since . There are 1 older and 7 younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences, Inc. is Richard Brudnick, 64, who is the Chief Bus. Officer & Head of Corp. Strategy.
Douglas's mailing address filed with the SEC is C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140.
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch... a Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak BioSciences executives and other stock owners filed with the SEC include: